Σημειώσεις επεισοδίου
Send us Fan Mail In this episode of Clot Conversations, Dr. Lana Castellucci, University of Ottawa, discusses the COBRRA study, which compares the bleeding risks of rivaroxaban and apixaban in patients with acute VTE. The study follows patients for three months and finds that apixaban significantly reduces combined bleeding events compared to rivaroxaban. While the trial wasn't powered for individual outcomes, it shows no difference in VTE recurrence. This is potentially practice-changing inf...

